1
|
Krasnov VP, Nizova IA, Vigorov AY, Matveeva TV, Levit GL, Kodess MI, Ezhikova MA, Slepukhin PA, Bakulin DA, Tyurenkov IN, Charushin VN. Synthesis and Assessment of Antiplatelet and Antithrombotic Activity of 4-Amino-Substituted 5-Oxoproline Amides and Peptides. Molecules 2023; 28:7401. [PMID: 37959820 PMCID: PMC10648734 DOI: 10.3390/molecules28217401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 10/30/2023] [Accepted: 11/01/2023] [Indexed: 11/15/2023] Open
Abstract
Venous thromboembolism is a serious problem because it significantly increases the risk of developing vascular complications in elderly patients with obesity or immobilization, cancer, and many other diseases. Thus, there is a need to study new therapeutic strategies, including new medicinal agents for the efficient and safe correction of thrombus disorders. In this work, we have synthesized a number of new amides and peptides of 4-amino-5-oxoprolines and studied their antiplatelet and antithrombotic activity in experiments in vitro and in vivo. It has been found that the newly obtained compounds slow down the process of thrombus formation in a model of arterial and venous thrombosis, without affecting plasma hemostasis parameters. (2S,4S)-4-Amino-1-(4-fluorophenyl)-5-oxoprolyl-(S)-phenylalanine proved to be the most efficient among the studied derivatives. The results obtained indicate the advisability of further studies on 5-oxoproline derivatives in order to design pharmaceutical agents for the prevention and treatment of the consequences of thrombosis.
Collapse
Affiliation(s)
- Victor P. Krasnov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Irina A. Nizova
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Alexey Yu. Vigorov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Tatyana V. Matveeva
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Galina L. Levit
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Mikhail I. Kodess
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Marina A. Ezhikova
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Pavel A. Slepukhin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
| | - Dmitry A. Bakulin
- Laboratory of Pharmacology of Cardiovascular Agents, Scientific Center for Innovative Medicines, Volgograd State Medical University, Volgograd 400131, Russia; (D.A.B.); (I.N.T.)
| | - Ivan N. Tyurenkov
- Laboratory of Pharmacology of Cardiovascular Agents, Scientific Center for Innovative Medicines, Volgograd State Medical University, Volgograd 400131, Russia; (D.A.B.); (I.N.T.)
| | - Valery N. Charushin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), Ekaterinburg 620108, Russia; (I.A.N.); (A.Y.V.); (T.V.M.); (G.L.L.); (M.I.K.); (M.A.E.); (P.A.S.); (V.N.C.)
- Chemical Engineering Institute, Ural Federal University, Ekaterinburg 620002, Russia
| |
Collapse
|
2
|
Vigorov AY, Nizova IA, Levit GL, Matveeva TV, Sadretdinova LS, Nazarov OI, Kovalev NS, Bakulin DA, Kurkin DV, Tyurenkov IN, Krasnov VP. Synthesis and study of antiplatelet and antithrombotic activity of 4-substituted pyroglutamic acids. Russ Chem Bull 2022. [DOI: 10.1007/s11172-022-3693-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
|
3
|
Design, Synthesis, and Evaluation of Novel L-Pyroglutamic Acid Derivatives as Potent Antifungal Agents. Chem Nat Compd 2021. [DOI: 10.1007/s10600-021-03553-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Pandey CP, Misra A, Negi MPS, Kanuri BN, Chhonker YS, Bhatta RS, Narain VS, Dikshit M. Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction. Indian J Med Res 2019; 150:50-61. [PMID: 31571629 PMCID: PMC6798616 DOI: 10.4103/ijmr.ijmr_782_17] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background & objectives: Cytochrome P450, P2Y12, cyclooxygenase-1 (COX1) and glycoprotein V1 (GPVI) gene polymorphisms are known to affect patient responsiveness towards aspirin and clopidogrel dual antiplatelet therapy (DAPT). The present study was undertaken to identify aspirin and clopidogrel non-responsiveness and its association with genetic polymorphism in patients with myocardial infarction (MI). Methods: A total of 207 MI patients who were on DAPT, were included. The DAPT non-responsiveness was determined by light transmittance aggregometry using arachidonic acid and adenosine diphosphate and high platelet reactivity by collagen. Platelet activation biomarkers, thromboxane B2 (TxB2) and soluble CD40 ligand (sCD40L) were measured in plasma. Patient compliance was checked by estimating drug and its metabolite levels (aspirin and clopidogrel) in plasma using liquid chromatography-mass spectrometry/mass spectrometry. Genomic DNA was extracted, amplified by polymerase chain reaction and subsequently sequenced to identify CYP450, P2Y12, COX1 and GPVI gene polymorphisms. Results: Of the 207 patients, 32 were non-responders. The DAPT non-responsiveness was found in 15.5 per cent patients. The non-responsiveness showed a significant and an independent association with gender [odds ratio (OR)=0.18, 95% confidence interval (CI)=0.01-0.78, P=0.023], TxB2 (OR=1.00, 95% CI=1.00-1.01, P=0.013), CYP2C19*2 G>A (OR=3.33, 95% CI=1.04-10.69, P=0.044) and GPVI T>C (OR=0.23, 95% CI=0.08-0.67, P=0.007) after adjusting the demographic, clinical and genetic confounding factors when assessed between non-responder and responder compliant patients. Interpretation & conclusions: The study showed a significant association of genetic polymorphisms (CYP2C19*2 G>A and GPVI T>C) with DAPT non-responsiveness in MI patients. The findings of this study need further validation in a large cohort of patients with clinical follow up.
Collapse
Affiliation(s)
- Chandra Prakash Pandey
- Divisions of Pharmacology, CSIR-Central Drug Research Institute; Department of Cardiology, King George Medical University, Lucknow, India
| | - Ankita Misra
- Divisions of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India
| | - Mahendra Pal Singh Negi
- Divisions of Toxicology & Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, India
| | | | - Yashpal Singh Chhonker
- Divisions of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, India
| | - Rabi Shanker Bhatta
- Divisions of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, India
| | | | - Madhu Dikshit
- Divisions of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India
| |
Collapse
|
5
|
Developments in inhibiting platelet aggregation based on different design strategies. Future Med Chem 2019; 11:1757-1775. [PMID: 31288579 DOI: 10.4155/fmc-2018-0345] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Platelet aggregation is the central event in hemostasis and thrombosis. Up to now, many agents inhibiting platelet aggregation have been approved for the treatment of thrombotic disorders. In this review, we mainly summarized the progress in the research of platelet aggregation inhibitors based on different design strategies. The advantage and challenge of corresponding targets are also discussed in this article. We hope more platelet aggregation inhibitors with efficacy and safety will be discovered in the future.
Collapse
|
6
|
Al-Matar HM, Dawood KM, Tohamy WM, Shalaby MA. Facile Assembling of Novel 2,3,6,7,9-pentaazabicyclo- [3.3.1]nona-3,7-diene Derivatives under Microwave and Ultrasound Platforms. Molecules 2019; 24:E1110. [PMID: 30897823 PMCID: PMC6471913 DOI: 10.3390/molecules24061110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 03/13/2019] [Accepted: 03/14/2019] [Indexed: 01/11/2023] Open
Abstract
Reactions of a series of 3-oxo-2-arylhydrazonopropanal derivatives with two molar ratio of ammonium acetate afforded a library of tetrasubstituted 2,3,6,7,9-pentaazabicyclo[3.3.1]nona- 3,7-diene derivatives in good to excellent isolated yields. The reaction was activated with triethylamine catalyst under three different heating modes: thermal, ultrasonic and microwave irradiating conditions in ethanol solvent. The structures of the isolated products were fully characterized by spectral and analytical data as well as X-ray single crystal of selected examples.
Collapse
Affiliation(s)
- Hamad M Al-Matar
- Chemistry Department, Faculty of Science, University of Kuwait, P.O. Box 5969, Safat 13060, Kuwait.
| | - Kamal M Dawood
- Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt.
| | - Wael M Tohamy
- Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo 12622, Egypt.
| | - Mona A Shalaby
- Chemistry Department, Faculty of Science, University of Kuwait, P.O. Box 5969, Safat 13060, Kuwait.
| |
Collapse
|
7
|
Gang FL, Zhu F, Li XT, Wei JL, Wu WJ, Zhang JW. Synthesis and bioactivities evaluation of l-pyroglutamic acid analogues from natural product lead. Bioorg Med Chem 2018; 26:4644-4649. [DOI: 10.1016/j.bmc.2018.07.041] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 07/22/2018] [Accepted: 07/24/2018] [Indexed: 10/28/2022]
|
8
|
Misra A, Prakash P, Aggarwal H, Dhankani P, Kumar S, Pandey CP, Pugh N, Bihan D, Barthwal MK, Farndale RW, Dikshit DK, Dikshit M. Anti-thrombotic efficacy of S007-867: Pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro. Biochem Pharmacol 2018; 148:288-297. [DOI: 10.1016/j.bcp.2018.01.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Accepted: 01/03/2018] [Indexed: 12/30/2022]
|
9
|
Rauzi F, Smyth E, Emerson M. Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo. Thromb Haemost 2017; 117:2283-2290. [PMID: 29212116 PMCID: PMC6193277 DOI: 10.1160/th17-04-0250] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Mouse models of thromboembolism are frequently used to investigate platelet function in vivo and, according to European Union (EU) legislation, must be conducted in the context of replacement, refinement and reduction. We have previously developed a refined real-time mouse model of thromboembolism as an alternative to models of thromboembolic mortality which inflict considerable pain and suffering. Real-time monitoring involves infusion of radiolabelled platelets into the circulation of anaesthetized mice, and platelet aggregation is measured as increases in platelet-associated counts in the pulmonary vasculature following injection of platelet agonists. This gives a definitive data set on the tissue localization and extent of platelet activation. We developed an additional, more simplistic alternative to mortality models based on blood microsampling which entails the measurement of circulating platelet counts following agonist stimulation. Blood microsamples were collected from the tail vein of anaesthetized mice at three different time points leading to a reduction in animal numbers. Platelet counts significantly dropped 1 minute after stimulation with collagen or thrombin and were restored over 10 minutes. These results correlate with those obtained via real-time monitoring and were confirmed by immunohistochemistry. Pre-treatment of mice with aspirin significantly inhibited the decrease in platelet counts following collagen. These data suggest that blood microsampling may be implemented as a simplistic refined alternative to mortality models of thromboembolism when specialized monitoring equipment, or use of radioactive isotopes for real-time monitoring, which remains the ‘gold standard’, is not feasible. Microsampling refines and reduces animal procedures in compliance with current EU legislation.
Collapse
Affiliation(s)
- Francesca Rauzi
- Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Erica Smyth
- Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Michael Emerson
- Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| |
Collapse
|
10
|
Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK. Novel Glycoprotein VI Antagonists as Antithrombotics: Synthesis, Biological Evaluation, and Molecular Modeling Studies on 2,3-Disubstituted Tetrahydropyrido(3,4-b)indoles. J Med Chem 2016; 60:322-337. [DOI: 10.1021/acs.jmedchem.6b01360] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Shome S. Bhunia
- Academy of Scientific and Innovative Research, New Delhi 110 025, India
| | | | | | | | | | | | - Aaruni Saxena
- Institut
für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany
| | - Thomas Hohlfield
- Institut
für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany
| | | | - Anil K. Saxena
- Academy of Scientific and Innovative Research, New Delhi 110 025, India
| |
Collapse
|